These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34563010)

  • 1. The Effect of Ranibizumab Loading Treatment on Vision-Related Quality of Life in Diabetic Macular Edema.
    Daldal H; Turkyilmaz M; Balikoglu Yilmaz M; Berberoglu U
    Clin Pract; 2021 Sep; 11(3):659-670. PubMed ID: 34563010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration.
    Daldal H
    Ther Adv Ophthalmol; 2022; 14():25158414221108021. PubMed ID: 35873278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study.
    Oshima Y; Ishibashi Y; Umeda N; Nagata T; Yoshida S; Uchio E; Kondo H; Sonoda KH; Ishibashi T
    BMC Ophthalmol; 2021 Jan; 21(1):58. PubMed ID: 33485320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Clin Ophthalmol; 2014; 8():1711-6. PubMed ID: 25228787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
    Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?
    Turkoglu EB; Celık E; Aksoy N; Bursalı O; Ucak T; Alagoz G
    J Diabetes Complications; 2015; 29(4):540-3. PubMed ID: 25817172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
    JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.
    Bertelmann T; Feltgen N; Scheffler M; Hufenbach U; Wiedon A; Wilhelm H; Ziemssen F
    Health Qual Life Outcomes; 2016 Sep; 14(1):132. PubMed ID: 27644469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Taiwan J Ophthalmol; 2021; 11(3):244-250. PubMed ID: 34703739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.
    Gomi F; Migita H; Sakaguchi T; Okada H; Sugawara T; Hikichi Y;
    Jpn J Ophthalmol; 2019 Nov; 63(6):437-447. PubMed ID: 31673841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life after macular translocation with 360 degrees peripheral retinectomy for age-related macular degeneration.
    Cahill MT; Stinnett SS; Banks AD; Freedman SF; Toth CA
    Ophthalmology; 2005 Jan; 112(1):144-51. PubMed ID: 15629835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice.
    Wang LL; Liu WJ; Liu HY; Xu X
    Chin Med J (Engl); 2015 May; 128(9):1154-9. PubMed ID: 25947396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema.
    Karatas G; Erden B; Cakir A; Bolukbasi S; Erdenoz S; Argon BD; Elcioglu MN
    Beyoglu Eye J; 2021; 6(3):229-235. PubMed ID: 35005521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
    Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.
    Lang GE; Berta A; Eldem BM; Simader C; Sharp D; Holz FG; Sutter F; Gerstner O; Mitchell P;
    Ophthalmology; 2013 Oct; 120(10):2004-12. PubMed ID: 23725735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone implant as an adjuvant therapy to ranibizumab loading dose in persistent diabetic macular edema.
    Cakir A; Erden B; Bolukbasi S; Bayat AH; Ozturan SG; Elcioglu MN
    Int Ophthalmol; 2019 Oct; 39(10):2179-2185. PubMed ID: 30470985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.